30 August 2024: ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following corporate update in regards the Company’s ongoing administration process (“Administration Process”) and notifies of the cancellation of the Company’s ordinary shares (“Ordinary Shares”) from trading on AIM.
05 February 2024: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following update in relation to its current business development, financing discussions and working capital position.
08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell derived Exosome Technologies, announces its unaudited interim results for the six months ended 30 September 2023.
In vivo data highlights the specific tissue and cellular targeting capabilities of ReNeuron’s stem cell derived exosome drug delivery platform, CustomEXTM
08 November 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron’s CustomEX™ drug delivery platform, at Cell 2023 in London.
Creating a valuable and differentiated Exosome Delivery Platform
04 September 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. The Company will now look to broaden its capabilities and focus on the functional delivery of specific payloads.
22 August 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.
24 July 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company’s website.
16 June 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2023 has today been sent to shareholders and is available to download on the Company’s website here: https://www.reneuron.com/investors/financial-reports/
Unaudited Preliminary Results for the year ended 31 March 2023
Creating a valuable and differentiated Drug Delivery Platform
25 May 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its unaudited preliminary results for the year ended 31 March 2023.
18 May 2023: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023.
For our archived news, click here
